NLRP3 and metabolic disease: Furthermore, omega-3 fatty acids and beta-hydroxybutyrate have been shown to prevent inflammation and metabolic disorders via inhibition of NLRP3 inflammasome activation (22, 23), whereas MCC950, RRx-001, oridonin, and tranilast can directly target NLRP3 to alleviate inflammasome-driven diseases (24, 25, 26, 27, 28, 29).